
网络出版日期: 2016-01-13
基金资助
国家自然科学基金(81371860)
Antiviral therapy in patients with hepatitis B virus-related liver cirrhosis
Online published: 2016-01-13
Supported by
National Natural Science Foundation of China, 81371860
谷雷雷 , 张欣欣 . 乙型肝炎肝硬化患者的抗病毒治疗[J]. 上海交通大学学报(医学版), 2015 , 35(11) : 1717 . DOI: 10.3969/j.issn.1674-8115.2015.11.024
Chronic hepatitis B virus (HBV) infection is one of the major causes of liver cirrhosis. The progression of cirrhosis is associated with the HBV DNA level. The antiviral therapy can inhibit the viral replication, reduce complications of cirrhosis, and improve the survival rate of patients with cirrhosis. It is important to provide effective antiviral therapy for the treatment of HBV-related liver cirrhosis. Currently, antiviral drugs include nucleos(t)ide analogues (Nucs) and IFNα. This paper briefly introduces the application of these antiviral drugs to patients with cirrhosis and particularly highlights the recommendations in native and foreign practice guidelines for the treatment of HBV-related liver cirrhosis.
/
| 〈 |
|
〉 |